Welcome to our dedicated page for Cadrenal Therape news (Ticker: CVKD), a resource for investors and traders seeking the latest updates and insights on Cadrenal Therape stock.
Cadrenal Therapeutics, Inc. (Nasdaq: CVKD) is a biopharmaceutical company developing anticoagulant therapies for rare and high-risk patient populations, and its news flow reflects this specialized focus. The CVKD news page on Stock Titan aggregates company announcements, sponsored coverage, and regulatory updates related to its clinical-stage pipeline.
Readers can expect news centered on Cadrenal’s three main assets: VLX-1005, a first-in-class 12-LOX inhibitor in Phase 2 development for heparin-induced thrombocytopenia (HIT); tecarfarin, an oral vitamin K antagonist for chronic use in patients with kidney dysfunction or left ventricular assist devices; and frunexian, a parenteral Factor XIa antagonist positioned for acute hospital settings. Company communications often highlight regulatory designations such as Orphan Drug and Fast Track status, clinical trial progress, and portfolio-expanding transactions.
News items also cover corporate developments, including participation in healthcare investor conferences, partnering outreach, and board-level appointments. Financial updates, such as quarterly results and capital-raising activities disclosed via press releases and Form 8-K filings, provide additional context on how Cadrenal is funding and prioritizing its development programs.
For investors, clinicians, and researchers following the evolution of anticoagulation therapies, the CVKD news feed offers a consolidated view of Cadrenal’s milestones across chronic, acute, and immune-mediated indications. Bookmark this page to review new press releases, sponsored analytical pieces, and SEC-related announcements as they are released, and to track how the company’s strategy and pipeline advance over time.
Cadrenal Therapeutics (Nasdaq: CVKD) highlighted research supporting its first-in-class 12-lipoxygenase (12-LOX) inhibitor, CAD-1005, as a potential approach to reduce obesity- and Type 2 diabetes‑related inflammation. Preclinical oral dosing showed improved glycemic control, preserved pancreatic β-cells, fewer inflammatory cells in adipose and pancreas, and lower adipose pro-inflammatory cytokines. Cadrenal acquired the 12-LOX portfolio in December 2025 and reported Phase 2 results showing reduced thrombotic events in suspected HIT. The company is developing next-generation CAD-2000.
Cadrenal Therapeutics (Nasdaq: CVKD) expanded its pipeline with a portfolio of selective 12-LOX inhibitors, including oral candidates, and reported encouraging blinded Phase 2 data for CAD-1005 in heparin-induced thrombocytopenia (HIT).
CAD-1005 showed a reduction in thrombotic events on standard anticoagulants and an End-of-Phase 2 (EOP-2) meeting is scheduled this month (March 2026). Management positions 12-LOX inhibition as a differentiated platform with potential acute and chronic applications across inflammatory and thrombotic diseases.
Cadrenal Therapeutics (Nasdaq: CVKD) reported Phase 2 results for CAD-1005 in heparin-induced thrombocytopenia (HIT) showing a >25% absolute reduction in thrombotic events versus placebo on top of standard anticoagulant therapy, despite no improvement in platelet count recovery. An End-of-Phase 2 FDA meeting is scheduled for March 2026 to align on a Phase 3 path. The trial was randomized, blinded, placebo-controlled and concluded in December 2025 after program transfer from Veralox. Detailed data will be presented at a future scientific meeting.
Cadrenal Therapeutics (NASDAQ: CVKD) highlighted the high incidence and clinical burden of thrombotic complications in heparin-induced thrombocytopenia (HIT) and promoted VLX-1005—acquired in December 2025—as the first highly selective 12-LOX inhibitor in clinical testing. Emerging Phase 2 data suggest VLX-1005 may reduce thrombotic complications in suspected HIT by targeting immune-driven platelet activation rather than only inhibiting coagulation.
VLX-1005 has Orphan Drug and Fast Track designations from the FDA and orphan status from the EMA; Cadrenal plans FDA discussions about a potential pivotal Phase 3 registration study. Cadrenal will also present at Lytham Partners on January 15, 2026.
Cadrenal Therapeutics (NASDAQ:CVKD) is positioning its pipeline as a hospital-focused anticoagulation platform on December 30, 2025. The company pairs a Phase 3-ready vitamin K antagonist, tecarfarin, aimed at renal-impaired and dialysis patients, with an acquired Factor XIa inhibitor portfolio for acute hospital care. Cadrenal also holds VLX-1005, a Phase 2 12-LOX inhibitor with Orphan Drug and Fast Track designations for heparin-induced thrombocytopenia (HIT). Together the assets span chronic, acute, and immune-mediated anticoagulation failures, targeting high-acuity hospital needs rather than broad-market incremental gains.
Cadrenal Therapeutics (NASDAQ:CVKD) is pursuing underserved anticoagulation patients with a three‑pillar pipeline targeting chronic, acute, and immune‑mediated thrombosis.
Key elements: a Phase 3‑ready vitamin K antagonist tecarfarin designed for kidney‑impaired and dialysis patients; an acquired Factor XIa inhibitor portfolio for acute hospital care; and VLX‑1005, a Phase 2 12‑LOX inhibitor for heparin‑induced thrombocytopenia with Orphan Drug and Fast Track designations.
The company positions this asset mix as a purpose‑built platform to address high‑risk patients where existing anticoagulants perform poorly.
Cadrenal Therapeutics (Nasdaq: CVKD) said management, including CEO Quang X. Pham, will hold partnering and investor meetings during the J.P. Morgan 44th Annual Healthcare Conference in San Francisco on January 12-15, 2026. The company highlighted two 2025 acquisitions and stated its focus on the $40 billion anticoagulation market.
Cadrenal's pipeline items cited: VLX-1005 (phase 2 IV 12-LOX inhibitor; ODD and Fast Track for HIT), tecarfarin (phase 3-ready oral VKA; ODD and Fast Track for ESKD with AFib; ODD for LVAD in collaboration with Abbott), and frunexian (phase 2-ready IV FXIa inhibitor for acute care).
Cadrenal Therapeutics (NASDAQ:CVKD) announced a quiet but material expansion of its clinical platform on December 12, 2025, advancing trial preparation, manufacturing, and clinical leadership.
The company added a Factor XIa program to target acute hospital anticoagulation and acquired VLX-1005, a Phase 2 asset with Orphan Drug and Fast Track designations for heparin-induced thrombocytopenia (HIT).
Management positions Cadrenal with complementary chronic and acute assets—tecarfarin for chronic care, Factor XIa for hospital use, and VLX-1005 for HIT—potentially shifting investor perception if clinical progress becomes visible.
Cadrenal Therapeutics (NASDAQ:CVKD) is expanding from a single-asset microcap into a multi‑asset anticoagulation platform addressing a $40 billion market.
The company acquired a Factor XIa portfolio for hospital use, bought VLX-1005 (Phase 2) with Orphan Drug and Fast Track designations for heparin‑induced thrombocytopenia, and is advancing tecarfarin toward Phase 3 readiness for difficult‑to‑treat chronic anticoagulation patients.
Management says these moves create chronic and acute care reach, multiple mechanistic approaches, and near‑term clinical catalysts that could prompt a market revaluation.
Cadrenal Therapeutics (NASDAQ: CVKD) announced on Dec 11, 2025 the acquisition of VLX-1005 and related 12-LOX assets from Veralox Therapeutics, adding a late-stage, first-in-class small‑molecule 12‑lipoxygenase inhibitor for heparin‑induced thrombocytopenia (HIT).
VLX-1005 has U.S. Orphan Drug and Fast Track designations, completed two Phase 1 studies showing favorable tolerability, and interim Phase 2 data reporting reductions in thromboembolic events. The release cites a $40 billion global anticoagulation market and an estimated $1 billion HIT market in the US and EU. Veralox may receive upfront, milestone payments and royalties upon commercialization.